Approved indications. Glofil-125 is FDA-approved as a diagnostic radiopharmaceutical to evaluate glomerular filtration in the diagnosis or monitoring of patients with renal (kidney) disease.

Off-label uses. It is used almost exclusively for its labeled purpose of measuring GFR; other uses are mainly in research settings and there are no well-established therapeutic or non-renal off-label indications.

Efficacy expectations. The drug itself does not treat kidney disease; it provides highly accurate GFR measurements that closely match inulin clearance and are more precise than estimates based on serum creatinine alone.

Time course and outcomes. The test is completed over a few hours, with results available once the collected blood and urine samples are analyzed, helping guide diagnosis, staging of kidney disease, and treatment decisions.

Comparison with alternatives. Compared with standard blood tests (creatinine, eGFR), Glofil-125 offers more accurate, direct measurement of GFR but requires specialized nuclear medicine facilities and exposes the patient to a small amount of radiation, so it is generally reserved for situations where precise GFR is needed.

Typical adult dosing. For an average 70‑kg adult, the suggested dose range is 10–30 µCi given as a single intravenous injection or 20–100 µCi given by continuous intravenous infusion, with the exact activity measured in a dose calibrator immediately before administration.

How it is given. Glofil-125 is injected into a peripheral vein (not a central venous catheter) by trained nuclear medicine staff in a hospital or imaging center. Patients are usually encouraged to drink fluids beforehand to ensure good urine output, and blood and urine samples are collected at specific times after the injection or during the infusion.

Special dosing and preparation instructions. The administered activity is individualized based on patient size, renal function, and the sensitivity of the detection equipment, and is corrected for radioactive decay on the day of use. Rapid, bolus-like injections are avoided to reduce local irritation and technical artifacts. Some protocols recommend short-term iodine supplementation (such as Lugol’s solution) before the test to limit thyroid uptake of any free iodide.

Missed dose or interrupted test. Because Glofil-125 is used for a single diagnostic study rather than ongoing therapy, if an appointment is missed or the dose is not fully administered, the procedure is typically rescheduled and the timing of blood and urine collections adjusted as directed by the imaging team.

Overdose management. In the uncommon event that more radioactivity than intended is administered, management usually focuses on maintaining good hydration and urine flow to promote elimination, combined with radiation-safety consultation and clinical monitoring until the excess exposure is deemed resolved.

Common side effects. In clinical use and product labeling, no specific adverse reactions have been reported; however, as with any intravenous injection, patients may experience brief discomfort, bruising, or irritation at the injection site.

Serious or rare adverse effects. Serious reactions are considered very rare but could include allergic or hypersensitivity reactions to iodinated compounds (such as sudden rash, swelling of the face or throat, trouble breathing, or chest tightness), which require immediate medical attention; there is also a small exposure to ionizing radiation, so use is limited to situations where the diagnostic benefit justifies that exposure.

Warnings and precautions. Glofil-125 must not be administered through a central venous line; it should be used only by clinicians trained in handling radiopharmaceuticals and minimizing radiation exposure. In pregnancy (Category C), it should be used only if clearly needed because fetal risks are unknown. During breastfeeding, radioiodine can enter breast milk, so formula feeding is recommended in place of breastfeeding around the time of the test. Safety and effectiveness in children have not been established, and use in infants is further limited by the presence of benzyl alcohol in the product. In patients with very poor kidney function, the tracer is cleared more slowly, so radiation exposure and test interpretation require specialist oversight.

Relative safety compared with other agents. Because the administered amounts are tracer doses, the risk of kidney injury and systemic effects is far lower than with high-volume iodinated contrast used for CT scans, but any prior severe reaction to iodinated contrast still warrants caution and careful risk–benefit assessment.

Side-effect reporting and safety updates. Patients should promptly tell their healthcare provider about any unexpected symptoms during or after the test; side effects can be reported to the FDA’s MedWatch adverse event reporting program, and updated safety information can be found on FDA drug safety resources or the drug’s DailyMed listing.

Drug and supplement interactions. No specific clinically significant drug–drug interactions are listed for Glofil-125, and because it is used in very small tracer doses, most prescription drugs, over-the-counter medicines, and supplements can usually be continued; nevertheless, patients should inform the nuclear medicine team about all medications, especially other iodinated contrast agents or iodine-containing products.

Food, beverages, and alcohol. Most protocols allow a normal diet and encourage clear fluids before and during the test to maintain urine flow; alcohol has no direct interaction but heavy drinking before the study may affect hydration and is generally discouraged.

Interactions with other procedures. Recent or planned diagnostic studies that use iodinated contrast or radioiodine (such as certain CT scans or thyroid imaging/treatment) should be discussed, because overlapping exposures can influence thyroid uptake of free iodide and affect overall radiation dose calculations.

Conditions requiring extra caution. Use during pregnancy requires careful justification because potential fetal effects of radiation are unknown; breastfeeding should be temporarily replaced with formula due to possible radioiodine in breast milk. Patients with a history of severe reactions to iodinated contrast media, uncontrolled asthma, or other serious allergies may need alternative methods or premedication. Those with very advanced kidney failure require expert interpretation and judicious dosing because the tracer is cleared more slowly.

Monitoring needs. During the study, staff closely track the timing of blood and urine collections and may monitor vital signs in higher-risk patients, but no routine long-term blood tests, ECGs, or blood pressure monitoring are needed solely because of Glofil-125 beyond standard clinical care.

Q: What is Glofil-125 used for?
A: Glofil-125 is a radioactive tracer injected into a vein so doctors can measure how well your kidneys filter blood (your glomerular filtration rate, or GFR) to help diagnose and monitor kidney disease.

Q: What will happen during the Glofil-125 test?
A: You will receive a small intravenous injection or infusion, then provide timed blood and urine samples over a few hours while you are encouraged to drink fluids; the procedure is usually done as an outpatient and does not require sedation.

Q: Will I be radioactive after the test, and do I need special precautions?
A: You will have a small amount of radioactivity in your body for a short time, which is gradually removed in the urine, and in most cases no special isolation is needed beyond good hygiene and following any specific instructions from the nuclear medicine team.

Q: Is Glofil-125 safe during pregnancy or breastfeeding?
A: Because the effects of this radiation exposure on an unborn baby are not known, Glofil-125 is used in pregnancy only if clearly necessary, and breastfeeding is usually paused and replaced with formula around the time of the test to avoid exposing the infant to radioiodine in breast milk.

Q: How accurate is this test compared with regular blood tests for kidney function?
A: Glofil-125 measurements closely match gold-standard inulin clearance and generally provide a more precise assessment of GFR than estimates based only on serum creatinine, so it is often reserved for situations where exact kidney function is particularly important.